Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept & continue
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
    Most Read
    • Saudi Arabia signals support for Russia’s role in Opec+ as sanctions pressure mounts
    • ‘Quad’ security group plans system to track illegal fishing by China
    • London Lawfare: how lawyers helped Russia’s super-rich
    • Anthony Albanese sworn in as Australia’s prime minister
    • Pennsylvania Senate race gets messy for Republicans after photo finish
  • US
    Sections
    • US Home
    • US Economy
    • US Companies
    • US Politics & Policy
    Most Read
    • ‘Quad’ security group plans system to track illegal fishing by China
    • Pennsylvania Senate race gets messy for Republicans after photo finish
    • Is the global economy heading for recession?
    • JPMorgan chief Jamie Dimon tries to rekindle Wall St glow at investor day
    • Why on earth did Warren Buffett swap Wells Fargo for Citigroup?
  • Companies
    Sections
    • Companies Home
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
    Most Read
    • HSBC suspends banker over climate change comments
    • Business leaders warn that three-decade era of globalisation is ending
    • Lukoil’s ex-chief warns against EU ban on ‘irreplaceable’ Russian oil
    • JPMorgan chief Jamie Dimon tries to rekindle Wall St glow at investor day
    • Capital Group’s €8bn European bank sell-off was driven by single fund manager
  • Tech
  • Markets
    Sections
    • Markets Home
    • Alphaville
    • Markets Data
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Fund Management
    • Trading
    • Moral Money
    • ETF Hub
    • Cryptocurrencies
    Most Read
    • Live news: UK minister refuses to rule out windfall tax on energy groups
    • The eternal dream of automatic money
    • How shadow banks threaten the global economy
    • Wall Street stocks flirt with bear market as growth concerns mount
    • Overdue reality check for Fed and markets has barely begun
  • Climate
  • Opinion
    Sections
    • Opinion Home
    • Columnists
    • The FT View
    • The Big Read
    • Lex
    • Obituaries
    • Letters
    Most Read
    • The cold call is back and worse than ever
    • The men who stick to a strict style diet
    • Why on earth did Warren Buffett swap Wells Fargo for Citigroup?
    • Davos and the new era of deglobalisation
    • Pessimism engulfs the Chinese economy as foreign investment fades
  • Work & Careers
    Sections
    • Work & Careers Home
    • Business School Rankings
    • Business Education
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
    Most Read
    • The cold call is back and worse than ever
    • ‘A bonfire of the decencies’: Peter Hennessy on Boris Johnson’s government
    • Vive la différence between work and play
    • Why presenteeism is an enduring corporate narcotic
    • As a longtime trailing spouse, how do I get back into full-time work?
  • Life & Arts
    Sections
    • Life & Arts Home
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
    Most Read
    • Short cuts: the little island becoming Europe’s aviation hotspot
    • The men who stick to a strict style diet
    • The HTSI summer 2022 travel special
    • Bridging loans surge as UK buyers scramble for property
    • Smart, co-operative, emotional: what cutting-edge science tells us about pigs
  • How to Spend It
  1. Companies
  2. Health
  3. Pharmaceuticals
MenuSearch
  • Home
  • World
  • US
  • Companies
  • Tech
  • Markets
  • Climate
  • Opinion
  • Work & Careers
  • Life & Arts
  • How to Spend It
Financial Times
SubscribeSign In

Your guide to a disrupted world

Start a 4-week trial

Pharmaceuticals sector

Add to myFT Digest

Add this topic to your myFT Digest for news straight to your inbox

  • Sunday, 22 May, 2022
    Disease control and prevention
    EU health agency advises member states to plan for monkeypox jabs

    Programmes would use smallpox vaccine and immunise close contacts of confirmed cases

  • Sunday, 22 May, 2022
    Coronavirus economic impact
    Big Pharma lobbies for slice of G20 fund to prepare for next pandemic

    Industry says it will reserve production capacity for low- income nations for a fee if border bans are ended

  • Thursday, 19 May, 2022
    UK politics & policy
    UK’s autumn Covid booster campaign could exclude most Britons

    JCVI’s provisional guidance limits top-up jabs to over-65s, frontline health workers and vulnerable younger people

  • Wednesday, 18 May, 2022
    Coronavirus pandemic
    How can Covid-19 affect the human brain?

    Scientists are trying to understand the cause of neurological effects and whether symptoms will be long-lasting

  • Wednesday, 18 May, 2022
    InterviewModerna
    Moderna chair defends executive hiring process after CFO fiasco

    Top finance director ousted after one day in job following emergence of probe at former employer

  • Saturday, 14 May, 2022
    News in-depthModerna
    Moderna CFO’s departure reignites debate over company’s culture

    Exit of Jorge Gomez after only a day in the job is latest in string of executives to leave biotech group

  • Wednesday, 11 May, 2022
    Moderna
    Moderna’s new CFO departs in first week in job

    Jorge Gomez leaves vaccine maker after former employer launches probe into financial reporting

  • Tuesday, 10 May, 2022
    LexPfizer Inc
    Pfizer: drugmaker puts Covid cash to work Premium content

    Pharma group’s chief is right to take advantage of the market sell-off to boost pipeline

  • Tuesday, 10 May, 2022
    Pfizer Inc
    Pfizer to buy biotech group Biohaven for $11.6bn

    US pharmaceutical group’s biggest deal in more than 5 years comes as sales of its Covid vaccine are set to fall

  • Monday, 9 May, 2022
    Covid-19 vaccines
    BioNTech beats forecasts on back of Covid vaccine demand

    German biotech maintains guidance but prepares for fall in sales because of jab oversupply

  • Wednesday, 4 May, 2022
    Moderna
    Moderna targets autumn release for Omicron vaccine

    US drugmaker says demand for ‘bivalent booster’ could lift jab sales in second half of 2022

  • Wednesday, 4 May, 2022
    Coronavirus treatment
    UK accused of leaving Covid immunocompromised ‘out to dry’

    Vulnerable people feel they are forgotten because of government’s ‘living with Covid’ strategy

  • Tuesday, 3 May, 2022
    Biogen Inc
    Biogen chief to step down after Alzheimer’s drug flops

    US biotech to dismantle sales infrastructure for treatment as it begins search for successor

  • Friday, 29 April, 2022
    LexEli Lilly & Co
    Obesity treatments: hunger-suppressing drugs whet investors’ appetite Premium content

    On paper the obesity drug market is huge but mass adoption of the treatments would strain health budgets

  • Friday, 29 April, 2022
    AstraZeneca PLC
    AstraZeneca sales beat forecasts on Covid jab demand

    Revenue rises 60% as Alexion acquisition and its rare diseases medicines boost drugmaker’s earnings

  • Friday, 29 April, 2022
    Commercial property
    World’s biggest property investors buy into ‘science superpower’ UK

    Tishman Speyer, Bellco and Brookfield among those increasing their bets on expanding life sciences

  • Thursday, 28 April, 2022
    Drugs research
    Eli Lilly says obesity drug has similar results to weight-loss surgery

    Late-stage trial of Tirzepatide could be a ‘potential breakthrough’ in treatment, says US drugmaker

  • Thursday, 28 April, 2022
    Special ReportThe Americas’ Fastest Growing Companies
    Healthcare joins leading pack of the Americas’ high-growth companies

    While tech still features prominently on the latest annual FT ranking, pharmaceuticals and health account for half the top 10

  • Wednesday, 27 April, 2022
    McKinsey rebuts conflict claims over work for health regulator and opioid makers

    Congressional probe found 22 consultants had advised both the US FDA and drug manufacturers over a decade

  • Wednesday, 27 April, 2022
    Moderna
    Moderna investors reject proposal to transfer vaccine tech

    Two top-10 shareholders say distribution problems not supply is reason for slower vaccination rates in low-income countries

  • Wednesday, 27 April, 2022
    Boots UK Ltd
    Apollo and Mukesh Ambani’s Reliance plan joint bid for Boots

    Private equity giant teams up with India’s largest company in attempt to buy UK pharmacy chain

  • Wednesday, 27 April, 2022
    GlaxoSmithKline PLC
    GSK beats forecasts on back of Covid and shingles treatments

    UK drugmaker points to ‘good momentum’ as sales rise by a third in ‘landmark year’

  • Tuesday, 26 April, 2022
    Special Report
    FT Health: Innovation in Healthcare

    The final instalment of our series on innovation in European healthcare examines the effects of the slump in biotech valuations and changes in EU health policy

  • Tuesday, 26 April, 2022
    Special ReportFT Health: Innovation in Healthcare
    Europe’s push to rival US biotech hubs faces hit from market slump

    Rout revives fears of American buyers swooping on the continent’s start-ups

  • Tuesday, 26 April, 2022
    Special ReportFT Health: Innovation in Healthcare
    Pandemic bolsters EU’s role in health policy

    ‘There has been a change in attitudes. There are a lot of initiatives that were not foreseen a couple of years ago’

Previous page You are on page 1 Next page

Topics related to Health & pharmaceuticals

Useful links

Support

View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

Legal & Privacy

Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

Services

Share News Tips SecurelyIndividual SubscriptionsGroup SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on TwitterFT TransactSecondary Schools

Tools

PortfolioToday's Newspaper (ePaper)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

Community & Events

FT CommunityFT LiveFT ForumsFT Board DirectorBoard Director Programme

More from the FT Group

Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2022. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
Financial Times

International Edition

Subscribe for full access
  • Switch to UK Edition
  • Top sections
  • Home
  • World
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
  • US
    • US Economy
    • US Companies
    • US Politics & Policy
  • Companies
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
  • Tech
  • Markets
    • Alphaville
    • Markets Data
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Fund Management
    • Trading
    • Moral Money
    • ETF Hub
    • Cryptocurrencies
  • Climate
  • Opinion
    • Columnists
    • The FT View
    • The Big Read
    • Lex
    • Obituaries
    • Letters
  • Work & Careers
    • Business School Rankings
    • Business Education
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
  • Life & Arts
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
  • Personal Finance
    • Property & Mortgages
    • Investments
    • Pensions
    • Tax
    • Banking & Savings
    • Advice & Comment
    • Next Act
  • How to Spend It
  • Special Reports
  • FT recommends
  • Lex
  • Alphaville
  • Lunch with the FT
  • FT Globetrotter
  • #techAsia
  • Moral Money
  • FTfm
  • Newsletters
  • Video
  • Podcasts
  • News feed
  • FT Community
    • FT Live
    • FT Forums
    • Board Director Programme
  • myFT
  • Portfolio
  • Today's Newspaper (ePaper)
  • Crossword
  • Our Apps
  • Help Centre
  • Subscribe
  • Sign In